Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.82 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 5/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762333 | 0.90 | ENPP1 (1.00) | ENPP1CA12CA14CA1CA7 | |
| SCHEMBL30117274 | 0.90 | ENPP1 (1.00) | ENPP1CA12CA14CA1CA7 | |
| SCHEMBL25656208 | 0.88 | ENPP1 (0.63) | ENPP1AAK1NSD2RETLRRK2 | |
| SCHEMBL25656202 | 0.82 | ENPP1 (0.56) | ENPP1CA12CA14CA1CA7 | |
| SCHEMBL25656004 | 0.81 | ENPP1 (0.54) | ENPP1LRRK2 | |
| SCHEMBL23726599 | 0.80 | ENPP1 (0.80) | ENPP1 | |
| SCHEMBL30117269 | 0.78 | ENPP1 (0.79) | ENPP1 | |
| SCHEMBL23762334 | 0.78 | ENPP1 (0.79) | ENPP1 | |
| SCHEMBL25656060 | 0.76 | ENPP1 (0.52) | ENPP1CA12CA14CA1CA7 | |
| SCHEMBL25656064 | 0.75 | ENPP1 (0.54) | ENPP1CA12CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885CA12 4183/4885CA14 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.